Compass Therapeutics (NASDAQ:CMPX) Sets New 52-Week High – Here’s Why

Compass Therapeutics, Inc. (NASDAQ:CMPX) reached a new 52-week high during trading on Wednesday . The company traded as high as $6.48 and last traded at $6.41, with a volume of 1795255 shares changing hands. The stock had previously closed at $6.19.

Analysts Set New Price Targets

CMPX has been the subject of a number of recent research reports. D. Boral Capital reiterated a “buy” rating and issued a $30.00 target price on shares of Compass Therapeutics in a report on Tuesday, January 6th. Lifesci Capital initiated coverage on Compass Therapeutics in a research report on Monday, October 6th. They set an “outperform” rating and a $10.00 price target on the stock. William Blair started coverage on Compass Therapeutics in a research report on Monday, January 5th. They issued an “outperform” rating for the company. Citizens Jmp assumed coverage on Compass Therapeutics in a research note on Wednesday, December 3rd. They set a “market outperform” rating and a $10.00 target price on the stock. Finally, Raymond James Financial reissued an “outperform” rating and issued a $9.00 price target on shares of Compass Therapeutics in a report on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Compass Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.23.

Compass Therapeutics Stock Up 3.6%

The company has a 50-day moving average of $5.42 and a 200 day moving average of $4.23. The stock has a market capitalization of $1.13 billion, a PE ratio of -14.18 and a beta of 1.45.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.06. As a group, equities analysts predict that Compass Therapeutics, Inc. will post -0.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

Several institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. raised its stake in shares of Compass Therapeutics by 3,933.7% in the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after acquiring an additional 7,592 shares in the last quarter. Creative Planning purchased a new stake in Compass Therapeutics during the 2nd quarter worth about $30,000. Flagship Harbor Advisors LLC acquired a new stake in Compass Therapeutics in the 4th quarter valued at about $32,000. Strs Ohio purchased a new position in shares of Compass Therapeutics in the 1st quarter valued at about $34,000. Finally, Apollon Wealth Management LLC purchased a new position in shares of Compass Therapeutics in the 3rd quarter valued at about $35,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.